The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance
Open accessAbstract
Summary: Clinical correlates and long‐term prognostic relevance of the JAK2V617F mutation was studied in 150 patients with essential thrombocythaemia (ET) from a single institution and followed for a median of 11·4 years. During this period, thrombotic complications were documented in 62 patients (41·3%) and transformation into acute myeloid leukaemia (AML), polycythaemia vera (PV), or myelofibrosis with myeloid metaplasia (MMM) occurred in 4 (2·7%), 8 (5·3%), and 15 (10%) patients, respectively. JAK2V617F was detected in either archived bone marrow or blood cells from 73 patients (48·7%) but none were homozygous for the mutant allele. Parameters at diagnosis that were significantly associated with the presence of JAK2V617F included advanced age and higher counts of both haemoglobin and leucocytes. During follow‐up, patients with the mutation were more likely to transform into PV but the incidences of AML, MMM, or thrombotic events were similar between patients with and without the mutation. Multivariate analysis identified advanced age, higher haemoglobin level, and thrombosis history but not the presence of JAK2V617F as independent predictors of inferior survival. Therefore, although the presence of JAK2V617F in ET appears to promote a PV phenotype, it might not carry treatment‐relevant information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationWidespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843 · cited 8×
“…the study cohort and the observed incidence was similar to those cited by previous studies with smaller number of cases; 32% (n ¼ 115) (Levine et al, 2005), 23% (n ¼ 93) (Kralovics et al, 2005), 41% (n ¼ 59) (Jones et al, 2005), 57% (n ¼ 51) (Baxter et al, 2005), 43% (n ¼ 21) (James et al, 2005).”
BackgroundResultInfluentialIdentification of an Acquired JAK2 Mutation in Polycythemia Vera
Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B., & Zhao, Z. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500138200 · Cited by 615
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
Elliott, M. A., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05277.x · Cited by 473
Self-citationSteensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F., Levine, R. L., Gilliland, D. G., & Tefferi, A. (2005) · Blood · doi:10.1182/blood-2005-03-1183 · Cited by 466
Self-citationPassamonti, F., Rumi, E., Pungolino, E., Malabarba, L., Bertazzoni, P., Valentini, M., Orlandi, E., Arcaini, L., Brusamolino, E., Pascutto, C., et al. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.06.032 · Cited by 447
Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
Fialkow, P., Faguet, G., Jacobson, R., Vaidya, K., & Murphy, S. (1981) · Blood · doi:10.1182/blood.v58.5.916.916 · Cited by 386
Cited by
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Self-citationTefferi, A., & Vardiman, J. W. (2008) · Leukemia · doi:10.1038/sj.leu.2404955 · Cited by 1,002
Self-citationThe Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R. M., Finazzi, G., Guerini, V., Fabris, F., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064287 · Cited by 449
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Self-citation
Metadata
- Authors
- Wolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2005-09-30
- Volume
- 131
- Issue
- 2
- Pages
- 208-213
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1981240373
- Cited by
- 303
- References
- 22
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance. https://app.cochat.ai/papers/10.1111/j.1365-2141.2005.05764.x
- The paper
- Wolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A. (2005). JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2005.05764.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.